Navigating Data Challenges In RNA Therapeutics: From Complexity To Clarity

This content is brought to you by Genedata, a Danaher Operating Company.

RNA therapy pipelines have expanded considerably since the COVID-19 mRNA vaccines, and discovery teams are responding with miniaturized assays, automation, and larger screening campaigns. Less discussed is what happens downstream. Assays once run by a single scientist are now spread across teams, results from different assay types must be reconciled, and conflicting outcomes (strong on-target activity alongside off-target effects, or efficient encapsulation with weak cellular uptake) have to be weighed against each other. This article looks at where analysis and workflow strain appears as throughput and organizational complexity grow together, and why general-purpose tools often struggle with RNA-specific assay formats.

See how these pressures take shape across modalities.